Skip to main content
SpringerLink
Log in

Palivizumab

A Viewpoint by Siva Subramanian

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Siva Subramanian KN, Weisman LE, Rhodes T et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17: 110–5

    Article  Google Scholar 

  2. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high risk infants. Pediatrics 1998; 102: 531–7

    Article  Google Scholar 

  3. Conor EM, Carlin D, Top FH et al. Questions about Palivizumab (Synagis). Reply. Pediatrics 1999; 103: 535

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division Pediatrics and Obstetrics and Gynaecology, Georgetown University Medical Centres, Washington, DC, 20007-2197, USA

    Siva Subramanian

Authors
  1. Siva Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Subramanian, S. Palivizumab. Drugs 58, 312 (1999). https://doi.org/10.2165/00003495-199958020-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958020-00010

Search

Navigation